Insights from changes in NDEV biomarkers of metabolism: effects of PPARγ and GLP1 receptor agonists on brain metabolism.

J Clin Endocrinol MetabSep 16, 2026
Clinical ResearchEndocrinologyPsychiatryOpen access

Audrey Evers, Kathleen Watson, Fahim Abbasi et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the effects of pioglitazone (PPARγ agonist) and liraglutide (GLP1 receptor agonist) on central nervous system insulin signaling in participants with unremitted depression and those at genetic risk for Alzheimer's disease. Significant increases in biomarkers were observed, with 77% of pioglitazone recipients showing mTOR (Ser2448) response compared to placebo.

Key findings

  • 77% of participants receiving pioglitazone showed mTOR (Ser2448) response compared to placebo.
  • Participants on liraglutide had significant increases in NDEV-associated phosphorylated Akt (Ser473) and mTOR (Ser2448; P = .04 and P = .025).
  • 40% and 30% of liraglutide participants showed biomarker response in Akt (Ser473) and mTOR (Ser2448), respectively.

Why it matters

Understanding the impact of PPARγ and GLP1 receptor agonists on brain metabolism may provide insights into potential therapeutic strategies for managing insulin resistance-related central nervous system disorders, including depression and Alzheimer's disease.

Source

PubMed · PMID 41992726Free full text on PubMed Central

Published in J Clin Endocrinol Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.